Anebulo Pharma Files 8-K: Material Agreement & Delisting Notice
Ticker: ANEB · Form: 8-K · Filed: Feb 24, 2025 · CIK: 1815974
| Field | Detail |
|---|---|
| Company | Anebulo Pharmaceuticals, Inc. (ANEB) |
| Form Type | 8-K |
| Filed Date | Feb 24, 2025 |
| Risk Level | high |
| Sentiment | mixed |
Sentiment: mixed
Topics: material-agreement, delisting-notice, regulatory-filing
TL;DR
Anebulo Pharma 8-K: Material deal signed, but watch out for potential delisting issues.
AI Summary
Anebulo Pharmaceuticals, Inc. filed an 8-K on February 24, 2025, reporting a material definitive agreement and a notice of delisting or failure to satisfy listing rules. The filing date for the earliest event reported is February 20, 2025. The company is incorporated in Delaware and its principal executive offices are located in Lakeway, TX.
Why It Matters
This filing indicates potential significant corporate actions, including a material agreement and issues related to stock exchange listing rules, which could impact the company's future operations and stock value.
Risk Assessment
Risk Level: high — The notice of delisting or failure to satisfy listing rules suggests significant financial or operational challenges that could lead to the company's stock being removed from an exchange.
Key Numbers
- 001-40388 — SEC File Number (Identifies the company's filing history with the SEC.)
- 85-1170950 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Anebulo Pharmaceuticals, Inc. (company) — Registrant
- February 20, 2025 (date) — Earliest event reported date
- February 24, 2025 (date) — Filing date
- Delaware (jurisdiction) — State of incorporation
- Lakeway, TX (location) — Principal executive offices address
FAQ
What is the nature of the material definitive agreement entered into by Anebulo Pharmaceuticals?
The filing does not specify the details of the material definitive agreement, only that one was entered into.
What specific listing rule or standard has Anebulo Pharmaceuticals failed to satisfy?
The filing does not provide specific details regarding which listing rule or standard has not been met.
What is the earliest date of the events reported in this 8-K?
The earliest date of the events reported is February 20, 2025.
Where are Anebulo Pharmaceuticals' principal executive offices located?
The principal executive offices are located at 1017 Ranch Road 620 South, Suite 107, Lakeway, TX 78734.
What is the company's state of incorporation?
The company is incorporated in Delaware.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on February 24, 2025 regarding Anebulo Pharmaceuticals, Inc. (ANEB).